FDA Approval Of Amylin Pharmaceuticals, Inc., Eli Lilly and Company, and Alkermes's Bydureon Diabetes Medicine Expected but Still Uncertain
NEW YORK -(Dow Jones)- The likely approval of a long-acting Type 2 diabetes treatment next week will affect three companies--Amylin Pharmaceuticals Inc. ( AMLN), Eli Lilly & Co. (LLY) and Alkermes Inc. (ALKS)--but the decision's significance to investors will take some time to determine.